Nuchido TIME+ takes a multi-ingredient approach to NAD support, using nicotinamide rather than an NMN-only or NR-only formula. It has a published human study that deserves a closer look than the headline alone.
The central distinction is between a measured biomarker change and a demonstrated improvement in health or lifespan. A small study can support further research without proving broad anti-aging claims.
The published trial is useful product-related evidence, with important size, assay, and commercial-involvement limitations. It does not establish longer life or superiority to other NAD products.
What is in the current product?
The ingredient page identifies nicotinamide with botanical and other components, including Sophora-derived flavonoids, alpha-lipoic acid, green-tea ingredients, and parsley-derived apigenin. Compare the current supplied label with the formulation used in a cited trial; a shared product name is not a guarantee of identical composition over time.
What did the 2024 study find?
The published randomized crossover trial had 26 completers and 28-day treatment periods. It reported increased whole-blood NAD using its main assay and explored additional biomarkers. A smaller 17-person subset measured by a different analytical method did not show a statistically significant NAD effect; the authors discussed reduced statistical power. These details temper a simple percentage headline.
Does that mean biological aging was reversed?
The study examined a glycosylation-based age marker, not whether participants lived longer or avoided age-related disease. It also had Nuchido funding and author involvement. Those relationships do not automatically invalidate the work, but they should be visible when interpreting it. A marker moving in a favorable direction is not the same endpoint as improved everyday function.
Price and subscription structure
The product page lists a 30-day supply at $65 and a 90-day subscription from $165. The latter works out to $55 per 30 days, but the displayed total is the larger commitment. Confirm refill timing and the complete label before ordering. The page also flags caffeine content, which matters when evaluating sleep-related experiences.
What remains uncertain?
The available trial does not establish that the current product is better than NMN, NR, or prescribed NAD routes. It also cannot predict an individual’s energy response. Review a multi-ingredient formula as a whole, particularly if you already use vitamins or botanical products. Our medication-interaction guide explains why a supplement category name is insufficient for that review.
Where it fits in a shortlist
Nuchido belongs among products with identifiable formulation and study details, not among plain NMN or NR capsules. Compare Elysium Basis for a different studied combination and Qualia for another complex formula. The over-50 comparison emphasizes practical fit and evidence limitations.
Sources & reading notes
Editorial source review updated September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Nuchido: TIME+ product Manufacturer offer and current product information; compare the supplied formulation with the version studied. Checked September 18, 2026.
- Nuchido: ingredient explanation Manufacturer identifies nicotinamide and additional botanical ingredients. Mechanism claims are not independent clinical verification. Checked September 18, 2026.
- Henderson et al. (2024): Nuchido TIME+ crossover trial Small, company-involved biomarker study with 26 completers and 28-day intervention periods; not a lifespan trial. Checked September 18, 2026.
- FDA: questions and answers on dietary supplements Regulatory categories and limits of premarket review.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.